Scholarlink

Background <p>Statins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (<i>HMGCR)</i>, the pharmacological target of statins, and the solute carrier organic anion transporter family, member 1B1 (<i>SLCO1B1)</i>, a key hepatic transporter, have been implicated in statin response and toxicity, their role in statin-associated diabetogenesis remains unclear.</p> Objective <p>To investigate the association of four common <i>HMGCR</i> variants (rs17671591, rs12916, rs17238484, and rs2303152) and the <i>SLCO1B1</i> (rs4149056) with the risk of NO-T2DM among statin-treated cohort.</p> Methods <p>In a matched case-control study, 194 adults receiving atorvastatin or rosuvastatin were enrolled. The cases were patients who developed NO-T2DM within four years of initiating statin therapy (<i>n</i> = 97), while controls remained diabetes-free after four years of use (<i>n</i> = 97). Participants were matched for age, sex, ethnicity, BMI, and statin intensity. Genotyping was performed using TaqMan assays, and associations were evaluated using genetic models, linkage disequilibrium (LD), and haplotype analyses.</p> Results <p>The <i>HMGCR</i> rs17238484 variant showed a nominal association with NO-T2DM in statin users. Carriers of the T allele (GT + TT) showed a lower risk compared with the GG genotype (OR = 0.56, 95% CI: 0.36–0.99, <i>P</i> = 0.044); however, this association did not remain significant after correction for multiple testing. Haplotype analysis identified that the T–T–T haplotype of rs17671591–rs17238484–rs12916 was significantly associated with reduced risk of NO-T2DM (OR = 0.12, 95% CI: 0.02–0.58, <i>P</i> = 0.009). Other <i>HMGCR</i> SNPs and <i>SLCO1B1</i> rs4149056 showed no significant associations.</p> Conclusion <p>These findings suggest that <i>HMGCR</i> haplotypes may be associated with NO-T2DM risk among statin users, further studies in larger and more diverse populations are needed to validate these results.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月11日

查看全文
  • Areej S. Albawa’neh,
  • Mais N. Alqasrawi,
  • Zeina N. Al-Mahayri,
  • Nour al dain Marzouka,
  • Lilas Dabaghie,
  • Dana Hamza,
  • Lubna Q. Khasawneh,
  • Virendra Misra,
  • Husam Ouda,
  • Bassam R. Ali

摘要

Background

Statins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the pharmacological target of statins, and the solute carrier organic anion transporter family, member 1B1 (SLCO1B1), a key hepatic transporter, have been implicated in statin response and toxicity, their role in statin-associated diabetogenesis remains unclear.

Objective

To investigate the association of four common HMGCR variants (rs17671591, rs12916, rs17238484, and rs2303152) and the SLCO1B1 (rs4149056) with the risk of NO-T2DM among statin-treated cohort.

Methods

In a matched case-control study, 194 adults receiving atorvastatin or rosuvastatin were enrolled. The cases were patients who developed NO-T2DM within four years of initiating statin therapy (n = 97), while controls remained diabetes-free after four years of use (n = 97). Participants were matched for age, sex, ethnicity, BMI, and statin intensity. Genotyping was performed using TaqMan assays, and associations were evaluated using genetic models, linkage disequilibrium (LD), and haplotype analyses.

Results

The HMGCR rs17238484 variant showed a nominal association with NO-T2DM in statin users. Carriers of the T allele (GT + TT) showed a lower risk compared with the GG genotype (OR = 0.56, 95% CI: 0.36–0.99, P = 0.044); however, this association did not remain significant after correction for multiple testing. Haplotype analysis identified that the T–T–T haplotype of rs17671591–rs17238484–rs12916 was significantly associated with reduced risk of NO-T2DM (OR = 0.12, 95% CI: 0.02–0.58, P = 0.009). Other HMGCR SNPs and SLCO1B1 rs4149056 showed no significant associations.

Conclusion

These findings suggest that HMGCR haplotypes may be associated with NO-T2DM risk among statin users, further studies in larger and more diverse populations are needed to validate these results.